

Supplementary table: HRs with 95% CIs for the association between osteoporosis and all-cause mortality within the COPD cohort of the HUNT Lung Study using HUNT2 post-bronchodilator spirometry measurements.

COPD classification	Person-years	Observed deaths	Death rate*	n**	Baseline HR	95% CI	Adjusted HR	95% CI
<i>GLI cohort±</i>								
Normal BMD	8 926	403	45.2	603			1.00 (Ref.)	
Osteopenia	1 777	127	71.5	157	1.47	1.17-1.84	1.26	0.97-1.63
Osteoporosis	2 042	160	78.4	178	1.27	0.97-1.65	1.09	0.80-1.49
<i>p- value for trend</i>					<i>0.042</i>		<i>0.391</i>	
<i>GOLD cohort§</i>								
Normal BMD	13 245	633	47.8	918			1.00 (Ref.)	
Osteopenia	2 626	187	71.2	225	1.42	1.18-1.71	1.19	0.96-1.48
Osteoporosis	3 495	253	72.4	290	1.32	1.07-1.64	1.09	0.84-1.41
<i>p-value for trend</i>					<i>0.006</i>		<i>0.392</i>	

* Per 1000 person-years.

** Count after completing missing data by multiple imputation.

†Adjusted for sex and continuous age upon entering the cohort.

†† Adjusted for all confounders including sex, continuous age, COPD severity (mild, moderate, severe, very severe, BMI (underweight, normal weight, overweight, obesity), tobacco smoking (never, former, current, with the latter two categories stratified by <10, 10-20 and >20 pack years), alcohol use (low, intermediate, high) , physical activity (inactive, low, medium, high), level of education (low, medium, high) and ever cardiovascular disease, diabetes, cancer, musculoskeletal or rheumatic disorders and chronic diseases affecting ADL(yes/no).

± GLI COPD defined by FEV1/FVC z-score <-1.64, as well as having symptoms of wheeze, sputum production and/or chronic cough.

§ GOLD criteria defined by FEV1/FVC ratio <0.70, as well as having symptoms of wheeze, sputum production and/or chronic cough.